Muna Therapeutics: #19 Debut
Muna Therapeutics debuted at #19 of 214 companies, score 36.67, with claim_integrity at 9.6 and independent_replication at 3, a 6.6-point gap between its strongest and weakest dimensions.
Muna Therapeutics entered the company rating this week at #19 of 214, score 36.67. Highest new entry of the week. Other newcomers: OneSkin (#32, 34.3), NuSirt (#52, 28.1), Life Length (#67, 22.9).
The company develops therapies against neurodegenerative diseases, Alzheimer's and Parkinson's included. The goal: slow or stop neurodegeneration, preserve cognition and other brain functions, resolve neuroinflammation, strengthen the brain's resistance to disease pathology. The MiND-MAP discovery and validation approach is all-in-human: single-cell spatial multi-omics, bioinformatics, structural biology, computational chemistry, cell-based screening.
Strongest dimension: claim_integrity 9.6. The company is careful about what it claims. Five more at 8 or above: ambition (8.3), falsifiability (8), implementation_fidelity (8), scandal_integrity (8), collaborativity (8). Weakest: independent_replication at 3. Middle ground: publicity 5, media_reach 4, pipeline_quality and publication_quality both at 6.
The gap between claim_integrity (9.6) and independent_replication (3) is 6.6 points. The top three (Attralus 46.0, Blue Rock Therapeutics 44.8, Medipost 44.4) sit 7.7 to 9.3 points ahead.
Full profile: https://eternalsearch.net/companies/fbjiPG8M
Highest-ranked new entry in the company rating this week, with the most extreme gap between claim_integrity (9.6) and independent_replication (3) in its profile, making it the clearest case of 'disciplined but unproven' this cycle.